Collage with one hundred dollars banknote in surreal style.

A Brief Political Economy of Hype

By Maxim Tvorun-Dunn

Silicon Valley depends on boom-and-bust cycles, manufacturing a new wave of investments every few months by promising grand technological revolutions, whether through AI, cryptocurrency, metaverses, or any other buzzword of the tech industry. These bubbles are furnished by media narratives and tech journalism. Through uncritical reporting of press releases and overexaggerating claims, news outlets help tech industrialists inflate their stock portfolios, while regularly ignoring the politics of privatization and automation. Reporting on psychedelics has followed similar trends, regularly positioning research on psychedelic therapy or drug manufacturing as Silicon Valley’s latest panacea.

Read More

Composite collage image of four peoples' hands holding lightbulb puzzle pieces.

Common Problems in Psychedelic Science, and How to Fix Them

By Eiko I. Fried and Michiel van Elk

Much optimism has been expressed about the potential of psychedelics to treat mental health problems such as suicidal ideation, depression, and post-traumatic stress disorder. This optimism goes hand in hand with a notable increase in research publications, investments from pharmaceutical companies, patent filings, media exposure, as well as shifts in political and legislative landscapes. In the U.S., hundreds of ketamine clinics have emerged in the last years, and Australia just recently acknowledged psychedelics as medicines.

In our new paper in print in the journal Therapeutic Advances in Psychopharmacology, titled “History repeating: Guidelines to address common problems in psychedelic science,” we critically discuss whether this optimism is warranted, given current empirical work. One of us (Dr. Eiko Fried) is an Associate Professor in Clinical Psychology who studies and teaches conducting and evaluating clinical trials for mental health problems such as depression, with a focus on the question what valid inferences can be drawn from empirical data. The other (Dr. Michiel van Elk) is an Associate Professor in Cognitive Psychology, with a long-standing interest in the topic of altered states of consciousness (including, but not limited to, states induced through psychedelics), who, together with the PRSM lab, uses a multi-method research approach, open science practices and replication studies to study these experiences in the lab and in naturalistic settings.

Read More

Doctor asking patient to fill out survey before medical treatment.

Psychedelics in the Clinical Setting: The Potential for Harm and the Promise of Healing

By Caroline Hayes

The psychedelic renaissance is well underway, with hundreds of clinical trials currently looking into a plethora of different mental health conditions. I was a sub-investigator on a clinical trial researching a psychedelic study drug to treat depression, but I have since stepped back from psychedelic clinical trials due to personal ethical concerns about the way the field is evolving. Despite the seemingly boundless optimism for their potential as pharmacological treatments, there are a number of unique issues that psychedelics present in a clinical setting that are yet to be adequately addressed. I believe it is essential that these issues are rectified to minimize the potential harm to those desperately seeking relief from their mood symptoms.

Read More

Fertilized human egg cells dividing.

What the Law and Bioethics Tell Us About Synthetic Human Embryos

By Barbara Pfeffer Billauer

A synthetic embryo can now be constructed from very early pre-embryonic cells – without the need for an egg or sperm. These were initially created in mice. In April, researchers in China published about their creation of synthetic monkey embryos. In June, it was reported that the first synthetic human models were apparently created. This development throws a moral monkey-wrench into the current moratoria on embryonic research after 14 days. But there are more problems ahead.

Read More

Hundred dollar bills rolled up in a pill bottle

Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment

By Nikhil Chaudhry and Reshma Ramachandran

Earlier this month, the Department of Health and Human Services announced that it had successfully included a reasonable pricing provision in a $326M investment contract with Regeneron for development of a next generation monoclonal antibody therapy for COVID-19. This was the first time the Biden Administration had included such a provision as part of its research funding agreements with the private sector, demonstrating that it is indeed possible for the federal government to negotiate deals with pharmaceutical companies that ensure that products developed with public dollars are priced comparably to the global market.

Read More

Biological hazard sticker on the doors to cell culture laboratory. Biohazard is a biological substance that poses a threat to the health of living organisms, primarily humans.

Biosafety Labs, Public Safety, and Politics

By Barbara Pfeffer Billauer

On May 25, 2023, merely six weeks before the Wuhan Biosafety lab lost its NIH funding amid the controversy of possible lab leaks and connection with COVID-19, the United States proudly opened the doors of the National Bio and Agro-Defense Facility (NBAF), the 14th biosafety level 4 lab in the U.S., and the first here that is capable of handling large animals.

The purpose: to research highly contagious diseases affecting animals and humans, such as foot and mouth disease. The NBAF will also feature a Biologics Development Module (BDM) to develop pilot vaccines and other countermeasures, and accelerate technology transfer to industry.

The location of this lab? Manhattan. Don’t be alarmed; it’s only Manhattan, Kansas, albeit adjacent to Kansas State University.

Read More

young african american woman suffering from abdominal pain while sitting on bed

‘Below the Belt’ Exposes the Silent Crisis of Endometriosis Care

By Timothy Bonis

Premiering tonight on PBS, the film Below the Belt sheds light on endometriosis by documenting four women’s experiences with the disease.

Endometriosis is a silent crisis. One in ten women have it, yet, on average, people with the condition see seven doctors before they get diagnosed. Many experience severe pain, and the disease costs the American economy $80 billion annually in lost productivity, but the standard treatments are outdated and ineffectual.

Below the Belt exposes the failures in practice and policy that have led to the poor state of endometriosis care. Medical students usually don’t learn about endometriosis in medical school, and as a result, most general practitioners can’t recognize it. The majority of gynecologists treat endometriosis with hormones — which have serious side effects and bring little relief — and an ineffective surgery called ablation. Others continue to recommend the 20th-century approach, a hysterectomy. This dismal selection of treatments reflects the state of endometriosis research; historically, the disease has received less than $10 million in research funding per year (compared to $1 billion for diabetes, an equally common condition among women).

Read More

ACCRA, GHANA: April 23, 2020 - The testing of samples for the coronavirus in a veterinary lab in Accra, Ghana.

Does It Really Matter How the COVID-19 Pandemic Started?

By Barbara Pfeffer Billauer

Throughout the COVID-19 pandemic, much air time and social media space has been allocated to the lab leak vs. natural spillover dispute regarding the origins of SARS-CoV-2.

To summarize briefly, the question is whether the pandemic was caused by a leak from a biosafety level (BSL) four lab in Wuhan, China, or whether it arose naturally as a consequence of a virus jumping from a bat to an animal and then to humans.

Given that the “truth” will likely never be known, and certainly not provable, the question becomes: is it important to seriously consider the lab leak theory?

The answer, I suggest, is an unabashed yes — but not for the reason you might think. The question is important prospectively, not retrospectively. Debating the origins of the COVID-19 pandemic is a fool’s errand. Considering laboratory accidents writ large, however, is important, as they remain a potent threat to international biosecurity.

Read More

Gamblers make bets at the roulette table in a casino.

We All Stand to Benefit from Biden’s $2 Billion Bet on the Bioeconomy

By Matthew Chun

Business is bustling for biotechnology and biomanufacturing. On September 12, 2022, President Biden signed an executive order, launching a “whole-of-government approach to advance biotechnology and biomanufacturing.” And two days later, he backed it up with a national summit and a $2 billion spending plan.

But who stands to benefit from this large commitment of federal money? We all do.

Read More

Gloved hand grabs beaker with rolled currency.

Rethinking Funding for Scientific Innovation

By Matthew Bauer

Academic science laboratories typically survive by applying for private- and government-funded grants. This model of funding scientific innovation is being flipped on its head with the creation of the Arc Institute in Palo Alto.

Research labs no longer need to apply for highly competitive processes for grants. Instead, the Arc Institute aims to put science first, by funding its scientific investigators’ salaries and research costs for 8 years.

Read More